Prospective Multi-country Observational Study to Investigate the Impact of Abiraterone Acetate and Enzalutamide on Health-related Quality of Life, Patient-reported Outcomes, and Medical Resource Use in Metastatic Castration-resistant Prostate Cancer Patients
Active, no longer recruiting
Phase of Trial: Phase IV
Latest Information Update: 12 Sep 2017
At a glance
- Drugs Abiraterone acetate (Primary) ; Enzalutamide; Prednisone
- Indications Prostate cancer
- Focus Adverse reactions
- Acronyms AQUARiUS
- Sponsors Janssen Pharmaceutica
- 12 Sep 2017 Initial results from AQUARIOUS trial presented at the 42nd European Society for Medical Oncology Congress
- 29 Jun 2017 Planned End Date changed from 28 Feb 2018 to 21 Mar 2018.
- 07 Jun 2017 Status changed from recruiting to active, no longer recruiting.